BioNano Genomics Inc vs IQIYI Inc - ADR — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while IQIYI Inc - ADR trades at $1.19 (market cap $1.12B). The key difference: IQIYI Inc - ADR is far larger — about 84.8× BioNano Genomics Inc's market cap, and IQIYI Inc - ADR is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | IQ | |
|---|---|---|
Market Cap | $13.20M | $1.12B |
Sector | Health | Media |
52-Week High | $4.92 | $2.79 |
52-Week Low | $1.09 | $0.96 |
Enterprise Value | $15.81M | $2.69B |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
iQIYI (IQ) trades at $1.13 with no recent price movement, showing mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported Q1 2026 revenue decline of 13% year-over-year to $915.2M, missing expectations, though it beat EPS estimates. Valuation metrics show a high P/E ratio of 144.05 but attractive P/S of 0.29 and P/B of 0.57. Recent leadership changes and AI platform expansion highlight strategic shifts amid challenging fundamentals.
The outlook remains cautious with declining revenues and negative profitability margins creating headwinds. Analyst consensus leans bullish with 50% buy ratings, but execution risks and competitive pressures in China's streaming market pose significant challenges. The stock's current valuation disconnect between high P/E and low price-to-sales metrics suggests potential for recovery if AI initiatives drive growth, but near-term volatility is expected.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →